EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Evaluation of 5F-αMe-3BPA for Improving Pharmacokinetics in Boron Neutron Capture Therapy

Naoya Kondo iD, Fuko Hirano iD, Saki Iritani, Kensuke Suzuki, Anna Miyazaki iD, Takashi Temma iD

Pharmaceutics · 15.05.2026 · 18 (5) · 604

DOI: 10.3390/pharmaceutics18050604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.05.2026. Verfasst von Naoya Kondo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takat…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Osaka Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Boron neutron capture therapy (BNCT) relies on the selective delivery of boron-10 to tumor cells. Although 4-[10B]borono-L-phenylalanine (BPA) is currently the only clinically approved BNCT agent, it is limited by poor L-type amino acid transporter 1 (LAT1)/LAT2 selectivity and aqueous solubility. We previously developed 3-borono-5-fluoro-α-methyl-L-phenylalanine (5F-αMe-3BPA), a novel BPA derivative designed to be a LAT1-targeted BNCT/positron emission tomography theranostic agent. This study comprehensively characterizes its pharmacological profile and explores its pharmacokinetic optimization by modulating renal organic anion transporter 1 (OAT1).

Methods

Transport kinetics of BPA, related analogs, and 5F-αMe-3BPA were analyzed in HEK293 cells stably expressing LAT1 or LAT2 using Michaelis–Menten analysis. Time-dependent cellular uptake and intracellular retention of BPA and 5F-αMe-3BPA were evaluated in T3M-4 pancreatic cancer cells with or without the LAT1 inhibitor JPH203. In vivo biodistribution was examined in T3M-4 tumor-bearing mice after intravenous administration of 5F-αMe-3BPA or BPA, with assessment of probenecid pretreatment.

Results

5F-αMe-3BPA retained LAT1 affinity comparable to that of BPA while showing markedly reduced LAT2-mediated transport, indicating improved LAT1/LAT2 selectivity. In T3M-4 cells, 5F-αMe-3BPA showed stronger LAT1 dependence, higher steady-state accumulation, and better intracellular retention than BPA under amino acid-containing conditions. Although 5F-αMe-3BPA achieved favorable tumor-to-plasma and tumor-to-muscle ratios in vivo, it was rapidly cleared from circulation. Probenecid pretreatment increased plasma exposure, reduced early renal accumulation, and significantly enhanced tumor boron accumulation, reaching approximately twofold higher levels than control.

Conclusions

These findings establish 5F-αMe-3BPA as a highly LAT1-selective BNCT candidate and identify probenecid pretreatment as a clinically translatable pharmacokinetic strategy for maximizing therapeutic boron delivery.

Schlagwörter

Stichwörter der Autor:innen

L-type amino acid transporter 1 (LAT1)boron neutron capture therapy (BNCT)borono-phenylalanine (BPA)organic anion transporter 1 (OAT1)probenecid

Autor:innen und Institutionen

  • Department of Biofunctional Analysis, Graduate School of Pharmaceutical Sciences, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki 569-1094, Osaka, Japan.
  • Division of Fundamental Technology Development, Near InfraRed Photo-ImmunoTherapy Research Institute, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Osaka, Japan.
  • Stella Pharma Corporation Sakai R&D Center, Bldg. C-23, 1-1 Gakuen-cho, Naka-ku, Sakai 599-8531, Osaka, Japan.
  • Laboratory of Quantum Biological Analysis, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010 Asashiro Nishi, Kumatori, Sennan-gun 590-0494, Osaka, Japan.

ORCID-Profile: Naoya Kondo, Fuko Hirano, Anna Miyazaki, Takashi Temma

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Osaka Cancer Society
  • Stella pharma corporation
  • JSPS KAKENHI
  • Kyoto University in the Translational Research Program from AMED

Zitieren

APA

Kondo, N., Hirano, F., Iritani, S., Suzuki, K., Miyazaki, A., & Temma, T. (2026). Preclinical Evaluation of 5F-αMe-3BPA for Improving Pharmacokinetics in Boron Neutron Capture Therapy. Pharmaceutics, 18(5), 604. https://doi.org/10.3390/pharmaceutics18050604

Vancouver

Kondo N, Hirano F, Iritani S, Suzuki K, Miyazaki A, Temma T. Preclinical Evaluation of 5F-αMe-3BPA for Improving Pharmacokinetics in Boron Neutron Capture Therapy. Pharmaceutics. 2026;18(5):604. doi:10.3390/pharmaceutics18050604

BibTeX
@article{Kondo2026,
  author = {Kondo, Naoya and Hirano, Fuko and Iritani, Saki and Suzuki, Kensuke and Miyazaki, Anna and Temma, Takashi},
  title = {Preclinical Evaluation of 5F-αMe-3BPA for Improving Pharmacokinetics in Boron Neutron Capture Therapy},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {604},
  doi = {10.3390/pharmaceutics18050604}
}
Kostenlos starten →